Published in Expert Opin Investig Drugs on March 01, 2013
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol (2013) 1.10
Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care (2014) 0.99
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia (2016) 0.98
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol (2015) 0.98
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context (2014) 0.89
Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Front Pharmacol (2014) 0.86
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One (2016) 0.85
Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. Ther Clin Risk Manag (2017) 0.81
Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight. Indian J Endocrinol Metab (2015) 0.79
Novel Agents for the Treatment of Type 2 Diabetes. Diabetes Spectr (2014) 0.78
Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects. PLoS One (2015) 0.75
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Des Devel Ther (2017) 0.75
Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus. Diabetes Metab Syndr Obes (2017) 0.75
Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases. Toxicol Pathol (2010) 1.45
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2012) 0.95
The intravenous glucose tolerance test in cannulated Wistar rats: a robust method for the in vivo assessment of glucose-stimulated insulin secretion. J Pharmacol Toxicol Methods (2008) 0.94
Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol (2004) 0.93
Acetyl group availability influences phosphocreatine degradation even during intense muscle contraction. J Physiol (2004) 0.87
The acetyl group deficit at the onset of contraction in ischaemic canine skeletal muscle. J Physiol (2002) 0.87
Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol (2011) 0.87
The glycogenic action of protein targeting to glycogen in hepatocytes involves multiple mechanisms including phosphorylase inactivation and glycogen synthase translocation. J Biol Chem (2004) 0.86
Acetyl-CoA provision and the acetyl group deficit at the onset of contraction in ischemic canine skeletal muscle. Am J Physiol Endocrinol Metab (2004) 0.85
Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis: characterisation of the glucose excursion after glucagon challenge. J Pharmacol Toxicol Methods (2006) 0.84
Manganese enhancement in non-CNS organs. NMR Biomed (2010) 0.83
Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med (2012) 0.81
The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle. J Physiol (2002) 0.78
Reversibility of hyperglycaemia and islet abnormalities in the high fat-fed female ZDF rat model of type 2 diabetes. J Pharmacol Toxicol Methods (2010) 0.77
Glucagon challenge in the rat: a robust method for the in vivo assessment of Glycogen phosphorlyase inhibitor efficacy. J Pharmacol Toxicol Methods (2006) 0.77
Bicarbonate-induced alkalosis augments cellular acetyl group availability and isometric force during the rest-to-work transition in canine skeletal muscle. Exp Physiol (2002) 0.75